Active Ingredient History

  • Now
Sivifene is a small-molecule antineoplastic agent and immunomodulator that was under development in the 2000s by Tigris Pharmaceuticals as a topical treatment for cutaneous cancer metastases. It was specifically being investigated to treat high-grade squamous intraepithelial lesions (HSIL) associated with human papillomavirus (HPV) infection and invasive carcinomas of the anogenital area such as cervical, vaginal, and anal cancers. The drug reached phase II clinical trials prior to its discontinuation.   Wikipedia

  • SMILES: Oc1ccc(cc1)C(=NNc2ccc(cc2[N+](=O)[O-])[N+](=O)[O-])c3ccc(O)cc3
  • Mol. Mass: 394.34
  • ALogP: 3.78
  • ChEMBL Molecule:
More Chemistry
4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone | a007 | a 007 | a-007 | sivifene


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue